NPI: 1740447945 · SAN DIMAS, CA 91773 · General Acute Care Hospital · NPI assigned 05/16/2008
Authorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
| Authorized Official | DOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL) |
| NPI Enumeration Date | 05/16/2008 |
Other providers sharing the same authorized official: DOAN, CHRISTOPHER
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 26,678 | $420K |
| 2019 | 24,026 | $430K |
| 2020 | 17,579 | $318K |
| 2021 | 20,727 | $377K |
| 2022 | 24,347 | $466K |
| 2023 | 25,774 | $491K |
| 2024 | 23,341 | $413K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 0450 | Emergency room services | 26,446 | 24,063 | $980K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,983 | 1,935 | $191K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,073 | 2,015 | $175K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,746 | 3,541 | $151K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2,988 | 2,683 | $107K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5,020 | 4,727 | $91K |
| 99199 | Unlisted special service, procedure or report | 2,604 | 2,375 | $88K |
| 80053 | Comprehensive metabolic panel | 9,010 | 8,422 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,759 | 4,524 | $72K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3,081 | 2,933 | $71K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 1,330 | 1,263 | $66K |
| 71045 | Radiologic examination, chest; single view | 5,729 | 5,493 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11,226 | 10,451 | $58K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3,056 | 2,824 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,481 | 1,431 | $52K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 952 | 910 | $48K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 441 | 422 | $41K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 271 | 254 | $40K |
| Z7502 | 898 | 876 | $34K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,538 | 2,371 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 480 | 449 | $24K |
| 84484 | 3,528 | 3,266 | $24K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 263 | 240 | $22K |
| 83880 | 1,125 | 1,087 | $20K | |
| 83690 | 3,923 | 3,695 | $18K | |
| J3490 | Unclassified drugs | 4,351 | 2,925 | $18K |
| 81025 | 4,357 | 4,141 | $17K | |
| 83605 | 2,358 | 2,033 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,535 | 4,319 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,354 | 2,272 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,573 | 2,419 | $12K |
| 0250 | 3,476 | 2,607 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 954 | 900 | $12K |
| 0270 | 2,734 | 1,984 | $12K | |
| 87040 | 1,410 | 1,144 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,930 | 1,432 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,767 | 1,686 | $11K |
| 99070 | 381 | 201 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2,019 | 1,761 | $10K |
| 86710 | 947 | 875 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 202 | 198 | $8K |
| 85730 | 2,020 | 1,970 | $8K | |
| 81000 | 3,470 | 3,313 | $8K | |
| 85610 | 2,587 | 2,511 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,203 | 2,069 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 838 | 800 | $5K |
| 70140 | 31 | 26 | $5K | |
| 80076 | 928 | 893 | $5K | |
| 82150 | 964 | 940 | $4K | |
| 82397 | 411 | 403 | $4K | |
| 0011A | 101 | 98 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 201 | 188 | $3K |
| 82550 | 598 | 586 | $3K | |
| 81003 | 2,112 | 2,044 | $3K | |
| 87081 | 697 | 679 | $3K | |
| 86403 | 361 | 354 | $2K | |
| 81001 | 1,195 | 1,151 | $2K | |
| 0012A | 61 | 60 | $2K | |
| 86140 | 625 | 602 | $2K | |
| Z9725 | 74 | 74 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12 | 12 | $2K |
| 74018 | 121 | 116 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 613 | 561 | $2K |
| 84702 | 255 | 234 | $2K | |
| 73030 | 94 | 90 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 742 | 721 | $2K |
| 73610 | 96 | 93 | $2K | |
| 90715 | 53 | 53 | $2K | |
| 84703 | 346 | 336 | $2K | |
| 73630 | 62 | 61 | $1K | |
| 81002 | 573 | 542 | $1K | |
| 0360 | 204 | 197 | $1K | |
| 73564 | 51 | 51 | $989.95 | |
| 85379 | 139 | 133 | $904.99 | |
| 87186 | 165 | 161 | $895.38 | |
| J2060 | Injection, lorazepam, 2 mg | 213 | 190 | $822.27 |
| 0300 | 12 | 12 | $796.92 | |
| 72100 | 26 | 25 | $768.89 | |
| 99499 | 15 | 12 | $744.00 | |
| 71046 | Radiologic examination, chest; 2 views | 39 | 38 | $610.30 |
| 87420 | 120 | 115 | $596.57 | |
| 0320 | 44 | 41 | $550.26 | |
| 82962 | 287 | 263 | $529.35 | |
| 73130 | 26 | 25 | $516.41 | |
| 36415 | Collection of venous blood by venipuncture | 475 | 442 | $499.19 |
| 82009 | 124 | 118 | $375.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 126 | 121 | $371.94 |
| 0636 | 87 | 79 | $369.35 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 207 | 203 | $361.71 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 99 | 98 | $324.86 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 514 | 480 | $310.52 |
| 76376 | 536 | 498 | $300.63 | |
| 82948 | 138 | 130 | $296.17 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 38 | 38 | $266.11 |
| 86901 | 78 | 76 | $223.13 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 170 | 168 | $199.96 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 17 | 16 | $191.85 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 13 | 12 | $191.40 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 13 | 12 | $190.41 |
| 85027 | 37 | 36 | $158.42 | |
| A4649 | Surgical supply; miscellaneous | 40 | 29 | $147.15 |
| 81015 | 189 | 186 | $130.19 | |
| 96376 | 16 | 12 | $105.75 | |
| 86900 | 27 | 26 | $81.25 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 14 | 12 | $78.13 |
| 85651 | 25 | 24 | $63.44 | |
| 85007 | 24 | 24 | $50.46 | |
| 29125 | 12 | 12 | $50.00 | |
| 80061 | Lipid panel | 47 | 46 | $47.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 13 | 12 | $28.78 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 14 | 14 | $27.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 29 | 29 | $11.09 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 16 | 16 | $10.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | 13 | 12 | $10.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 90 | 88 | $8.78 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 97 | 92 | $3.66 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 14 | 13 | $0.83 |
| 88313 | 12 | 12 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 12 | 12 | $0.00 |
| 88312 | 12 | 12 | $0.00 |